INTENSITY THERAPEUTICS, INC. Operating Expenses
INTENSITY THERAPEUTICS, INC. (INTS) reported Operating Expenses of $3.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- INTENSITY THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $3.08M, a 14.01% increase year-over-year.
- INTENSITY THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $2.53M, a 25.57% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $3.14M, a 1.97% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $2.73M, a 23.45% decline year-over-year.
- INTENSITY THERAPEUTICS, INC. operating expenses for fiscal 2025 was $11.97M, a 27.81% decline from fiscal 2024.
- INTENSITY THERAPEUTICS, INC. operating expenses for fiscal 2024 was $16.59M, a 99.36% increase from fiscal 2023.
- INTENSITY THERAPEUTICS, INC. operating expenses for fiscal 2023 was $8.32M, a 10.19% increase from fiscal 2022.
- INTENSITY THERAPEUTICS, INC. operating expenses for fiscal 2022 was $7.55M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.08M 10-Q · filed 2026-08-11 | $5.61M 10-Q · filed 2026-08-11 | $8.75M derived: sum of 3 quarters · filed 2026-08-11 | $11.48M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $2.53M 10-Q · filed 2026-05-07 | $5.67M derived: sum of 2 quarters · filed 2026-05-07 | $8.40M derived: sum of 3 quarters · filed 2026-05-07 | $11.10M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $5.87M derived: sum of 2 quarters · filed 2026-03-27 | $8.58M derived: sum of 3 quarters · filed 2026-08-11 | $11.97M 10-K · filed 2026-03-27 | |||
| 2025-09-30 | $2.73M 10-Q · filed 2025-11-06 | $5.44M derived: sum of 2 quarters · filed 2026-08-11 | $8.83M 10-Q · filed 2025-11-06 | $12.04M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $2.71M 10-Q · filed 2026-08-11 | $6.10M 10-Q · filed 2026-08-11 | $9.30M derived: sum of 3 quarters · filed 2026-08-11 | $12.87M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $3.39M 10-Q · filed 2026-05-07 | $6.60M derived: sum of 2 quarters · filed 2026-05-07 | $10.17M derived: sum of 3 quarters · filed 2026-05-07 | $15.24M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $6.77M derived: sum of 2 quarters · filed 2026-03-27 | $11.84M derived: sum of 3 quarters · filed 2026-03-27 | $16.59M 10-K · filed 2026-03-27 | |||
| 2024-09-30 | $3.57M 10-Q · filed 2025-11-06 | $8.64M derived: sum of 2 quarters · filed 2025-11-06 | $13.38M 10-Q · filed 2025-11-06 | $16.73M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $5.07M 10-Q · filed 2025-08-07 | $9.81M 10-Q · filed 2025-08-07 | $13.16M derived: sum of 3 quarters · filed 2025-08-07 | $15.65M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $4.74M 10-Q · filed 2025-05-13 | $8.10M derived: sum of 2 quarters · filed 2025-05-13 | $10.59M derived: sum of 3 quarters · filed 2025-05-13 | $11.81M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $5.84M derived: sum of 2 quarters · filed 2025-03-13 | $7.06M derived: sum of 3 quarters · filed 2025-03-13 | $8.32M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $2.49M 10-Q · filed 2024-11-13 | $2.49M 10-Q · filed 2023-11-13 | $3.71M derived: sum of 2 quarters · filed 2024-11-13 | $4.97M 10-Q · filed 2024-11-13 | $4.97M 10-Q · filed 2023-11-13 | $6.44M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.22M 10-Q · filed 2024-08-08 | $1.22M 10-Q · filed 2023-08-14 | $2.48M 10-Q · filed 2024-08-08 | $2.48M 10-Q · filed 2023-08-14 | $3.95M derived: sum of 3 quarters · filed 2024-08-08 | $5.72M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $1.25M 10-Q · filed 2024-05-09 | $2.73M derived: sum of 2 quarters · filed 2024-05-09 | $4.50M derived: sum of 3 quarters · filed 2024-05-09 | $6.43M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.24M derived: sum of 2 quarters · filed 2024-03-14 | $5.17M derived: sum of 3 quarters · filed 2024-03-14 | $7.55M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $1.77M 10-Q · filed 2023-11-13 | $3.70M derived: sum of 2 quarters · filed 2023-11-13 | $6.08M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $1.93M 10-Q · filed 2023-08-14 | $4.31M 10-Q · filed 2023-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |